The GLP-1 Agonist Family
Exendin/GLP-1 Peptide Agonists — Incretin Axis and Structural SAR
## Overview
GLP-1 receptor agonists have emerged as transformative therapeutics for type 2 diabetes and obesity since exenatide's approval in 2005. They mimic endogenous glucagon-like peptide-1 (GLP-1), an incretin hormone secreted by L-cells of the distal small intestine in response to nutrient ingestion. By activating the GLP-1 receptor (GLP-1R), a class B GPCR, they stimulate glucose-dependent insulin secretion (glucose-lowering without hypoglycemia risk), suppress glucagon, delay gastric emptying (satiety), and exert central appetite-suppressant effects. The most recent agents (semaglutide, tirzepatide) achieve weight loss of 15–22%, rivaling bariatric surgery outcomes.
## Native GLP-1 and the DPP-4 Problem
Native GLP-1(7-36)amide is a 30-amino acid peptide with a plasma half-life of approximately 2 minutes, rapidly cleaved by dipeptidyl peptidase-4 (DPP-4) between Ala8 and Glu9. This negligible pharmacokinetic profile made native GLP-1 therapeutically impractical and drove the development of structural strategies to confer DPP-4 resistance. Two parallel approaches emerged: (1) exendin-4-based peptides with inherent DPP-4 resistance; and (2) human GLP-1 analogues with fatty acid conjugation for albumin-binding-mediated extension.
## Exenatide: From Gila Monster to Medicine
Exenatide is identical to exendin-4, a 39-amino acid peptide from the saliva of the Gila monster (*Heloderma suspectum*). Despite only 53% sequence identity with human GLP-1, it is a full GLP-1R agonist. Position 2 is Gly (not Ala), conferring DPP-4 resistance; the C-terminal 9-residue "Trp-cage" extension stabilizes the helical conformation and reduces renal clearance. Exenatide's t½ of ~2.4 hours required twice-daily injection; a weekly extended-release microsphere formulation (Bydureon) resolved this.
## Liraglutide to Semaglutide: Albumin Engineering
Liraglutide was the first human GLP-1 analogue with sufficient half-life (t½ ~13 h) for once-daily use. A C16 fatty acid is conjugated via a glutamate linker to Lys26 (with Lys34→Arg34 to prevent non-selective acylation), enabling reversible albumin binding (~98%) that dramatically slows renal clearance and proteolysis. **Semaglutide** amplified this strategy with a C18 diacid linked via a more complex miniPEG-γGlu-γGlu spacer—achieving >99% albumin binding and a t½ of ~165 hours, enabling once-weekly injection (Ozempic). The diacid enables tighter FcRn-mediated albumin recycling, further extending systemic exposure.
## Oral Semaglutide: Breaking the Peptide Oral Delivery Barrier
Oral semaglutide (Rybelsus) combined semaglutide with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), a novel absorption enhancer. SNAC transiently raises local gastric pH adjacent to the tablet, protecting peptide from peptic degradation, and simultaneously promotes transcellular absorption through gastric mucosa (bypassing intestinal proteases). This absorption strategy yields ~1% oral bioavailability—sufficient for therapeutic plasma levels given semaglutide's potency. It represents the first orally bioavailable GLP-1R agonist.
## Tirzepatide: Dual Incretin Agonism
Tirzepatide (Mounjaro/Zepbound) introduced the twin incretin concept—simultaneous agonism of GLP-1R and GIP (glucose-dependent insulinotropic polypeptide) receptor. Built on a modified GIP peptide backbone with 10 GLP-1-mimetic sequence elements, it uses a non-natural Aib2 (alpha-aminoisobutyric acid) at position 2 for complete DPP-4 resistance and a C20 fatty diacid for albumin binding (once-weekly dosing). GIP receptor agonism contributes adipose lipid mobilization and hepatic insulin sensitization beyond GLP-1 signaling, explaining tirzepatide's superior HbA1c reduction (−2.3% from baseline) and weight loss (−22.5% at 15 mg) in pivotal SURMOUNT trials.
## Key Takeaways
- Native GLP-1 t½ of 2 minutes is overcome by Gly2/Aib2 DPP-4 resistance or fatty acid albumin-binding extension
- Fatty acid conjugation strategy (liraglutide C16, semaglutide C18-diacid) exploits albumin-FcRn recycling for multi-day half-lives
- Oral semaglutide uses SNAC gastric absorption enhancement—the first oral peptide strategy for GLP-1R agonists
- Tirzepatide's dual GIP/GLP-1R agonism provides superior glycemic and weight outcomes vs monagonists
- Central appetite suppression via hypothalamic GLP-1R is a key mechanism behind the unprecedented weight loss efficacy
ملخص علاقة البنية بالنشاط
Key SAR findings for the GLP-1 agonist family:
- Native GLP-1(7-36)amide has a t½ of ~2 minutes due to DPP-4 cleavage at the Ala8-Glu9 bond; position 2 (Ala) modification or protection is the primary stability engineering target.
- Exendin-4 (exenatide) differs from GLP-1 at 9 positions and has Gly2 (not Ala2); the Gly2 and the His1 N-terminus together confer DPP-4 resistance and a t½ of ~2.4 h.
- Liraglutide adds a C18 fatty acid via a glutamate-linker at Lys26 (with Arg34 substitution): fatty acid enables albumin non-covalent binding (reversible), extending t½ to ~13 h for once-daily dosing.
- Semaglutide's C18 diacid fatty acid on the same Lys26 position (via miniPEG-γGlu-γGlu-miniPEG linker) achieves >99% albumin binding, extending t½ to ~165 h for once-weekly injection or oral administration.
- Oral semaglutide uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to transiently increase gastric pH and facilitate transcellular absorption through gastric mucosa—an unprecedented oral peptide strategy.
- Tirzepatide is a dual GIP/GLP-1 receptor agonist using a Cα-methyl Aib2 non-natural amino acid for DPP-4 resistance, with C20 fatty diacid for albumin binding; GIP agonism adds adipose and hepatic lipid metabolism benefit.